BofA Securities Downgrades PTC Therapeutics to Underperform from Neutral, Sets $38 Price Target

10:26AM ET 10/18/2021 MT Newswires
PTC Therapeutics (PTCT) has an average rating of outperform and price targets ranging from $38 to $75, according to analysts polled by Capital IQ.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here:

Price: 36.32, Change: -1.77, Percent Change: -4.65